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Aims: 
   Squamous cell carcinoma (SCC) of the oesophagus accounts for 28% of all 
oesophageal cancer cases in the UK.  The MRC OEO2 trial established the use 
of pre-operative Cisplatin and 5-fluoruracil chemotherapy prior to surgical 
resection and the use of pre-operative cisplatin-based chemo-radiotherapy has 
also been examined.  Long term results demonstrated 5 year survival rates of 
25.5% and 27.9% for cisplatin-based pre-operative chemotherapy and chemo-
radiotherapy respectively.  We sought to assess treatment delivery, survival 
outcomes and prognostic factors for oesophageal SCC patients treated with pre-
operative chemotherapy and surgical resection at a tertiary referral centre. 
 
Methods: 
   Pre-operative chemotherapy comprised of 2 cycles of CFU (Cisplatin 80mg/m2 
D1 and 5-fluorouracil 1000mg/m2/day D1-4). Baseline demographics, treatment 
details and clinical outcomes were collected and clinical and pathological factors 
predicting outcome were assessed. 
 
Results: 
   From January 2004 to December 2012, 73 patients with oesophageal SCC 
were treated with pre-operative chemotherapy followed by surgical resection. 
Patients at our centre were significantly older (p=0.035) and had a poorer 
performance status (p=0.023) compared to patients in the OEO2 trial.  Median 
age was 66 (range 44-81) and a higher proportion of female patients (43.8% v 
23.5%, p=0.0005) were treated at our centre.  70 (95.6%) patients completed two 
cycles of CFU chemotherapy with 67 (91.2%) patients proceeding to planned 
surgical resection.  The median overall survival was 32.6 months with a 5 year 
survival rate of 39%.  A clear circumferential margin and absence of 
lymphovascular invasion were statistically significant predictors of relapse free 
and overall survival. 
 
Conclusions: 
   Survival outcomes for SCC of the oesophagus at our centre were better than 
the published data for cisplatin-based pre-operative chemotherapy and chemo-
radiotherapy despite an older and less fit population. 
 
